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“The minute you think of giving up, think of the reason why you held on so 
long” 
 

ABSTRACT 
The purpose of this thesis was to study early and late side-effects to lung and heart in adjuvant loco-
regional radiation therapy (LRRT) of early breast cancer (BC). Papers I-III were intervention studies 
aiming to reduce symptomatic/ radiological pneumonitis and functional changes after LRRT by applying 
the ipsilateral lung dose volume constraint V20 ≤ 30 %. The results were compared with a previous 
treatment series. Papers IV-V evaluated the long-term cardio-pulmonary effects of BC RT. 
In paper I, 66 patients were followed for signs of post-RT pneumonitis and changes on chest computer 
tomography (CT) 4 months post-RT. Lung subvolumes with radiological changes were contoured and 
the mean doses were calculated. Few cases of symptomatic pneumonitis were diagnosed. The mean 
ipsilateral lung V20 was higher in symptomatic than in unaffected patients, 29 % vs 24 % (p=0.04). 
Mild/moderate radiological changes were detectable on chest CT in subvolumes with average doses > 30 
Gy.  
In paper II, patients were examined with chest X-ray and CT pre- and 4-5 months post-RT and compared 
to the outcome of our previous trial. The use of lung dose volume constraints significantly reduced 
moderate/severe radiological changes on chest X-ray compared with our earlier study (p< 0.001). Lung 
changes on CT were also limited in the present series and related to ipsilateral V13.  
In paper III, changes in pulmonary function tests (PFTs) were studied. The applied constraints appeared 
to lower short-term changes in PFTs. Pre-RT chemotherapy affected DLCO at baseline.  
In paper IV, a long-term follow-up of irradiated women with BC, i.e. median 11 years, was undertaken. 
We assessed late changes in PFTs and radiological abnormalities with chest CT. The median matched 
VC, FEV1, and TLC were reduced 15, 9, and 7 %, respectively, compared to pre-RT values (p<0.001). 
DLCO, however, appeared to recover from baseline probably due to transient chemotherapy-induced 
lung toxicity. The median matched percentage of the predicted DLCO 11 years after RT was, however, 
only 86 %, indicating a chronic therapy-induced reduction also of this metric. The observed radiological 
and PFTs changes 4 months after RT were, thus, still detectable after a median follow-up of 11 years.  
In paper V, the risk of developing ischaemic heart disease, through incidental heart irradiation, was 
examined in a population-based case-control study of 2,100 women, who underwent RT for BC during 
1958-2001. Individual patient data were obtained and doses to the entire heart and left anterior 
descending coronary artery were estimated. Exposure of the heart to ionizing radiation during RT 
increased the subsequent rate of ischaemic heart disease. The increase was proportional to the mean dose 
to the heart, began within a few years after exposure, and continued for at least 20 years.  
In conclusion, our aims to minimize incidental dose to lung in LRRT of BC lowered the short-term 
pulmonary side-effects and should therefore be utilized.  The long-term studies showed that side-effects 
to lung and heart after adjuvant RT in BC with older techniques were of clinical relevance still after 
several years.  
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Abbreviations 
AI                               Aromatase inhibitor 
BC                              Breast cancer 
 
BED                           Biologically effective dose 
 
CI                               Confidence interval 
 
CT                              Computer tomography 
 
CTV                           Clinical target volume 
 
DVH                          Dose volume histogram 
 
EORTC                      The European Organization for Research and Treatment of Cancer 
 
FEV1                          Forced expiratory volume in 1 second 
 
Gy                               Gray 
 
IMN                            Internal mammary lymph nodes 
 
ICRU                          International Commission on Radiation Units and Measurements 
 
IHD                             Ischaemic heart disease 
 
LAD                            Left anterior descending artery 
 
LRRT                          Loco-regional radiation therapy  
 
MD                              Mean dose 
 
NCI-CTC                    The National Cancer Institute Common Toxicity Criteria 
 
NTCP                          Normal tissue complication probability 
 
OAR                            Organ at risk 
 
QoL                             Quality of Life 
 
RIHD                          Radiation induced heart disease 
 
RP                               Radiation pneumonitis 
 
RT                               Radiation therapy 
 
Tam                             Tamoxifen 
1. Aims of the studies 
 
Study I. To study symptomatic and radiological pneumonitis in women with early 
breast cancer undergoing adjuvant loco-regional radiotherapy with lung dose-volume 
constraints. 
 
Study II. To evaluate post-irradiatory radiological lung changes on chest X-ray and CT 
in relation to Quality of Life, common dosimetric factors, and co-variates in adjuvant 
loco-regional radiotherapy with lung dose volume constraints for early breast cancer. 
 
Study III. To study changes in pulmonary function tests and symptomatic radiation 
pneumonitis after adjuvant loco-regional radiotherapy with lung dose volume 
constraints for early breast cancer. 
 
Study IV. To evaluate long-term functional and radiological changes after adjuvant 
loco-regional radiotherapy without lung dose volume constraints for early breast 
cancer. 
 
Study V. To estimate the risk of developing ischaemic heart disease after adjuvant 
radiotherapy in women with early breast cancer. 
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2. Introduction 
2:1 Adjuvant radiotherapy in breast cancer 
Breast cancer (BC) is a major global health problem among women with about 1.6 
million new cases annually (1). The incidence is also increasing. In Sweden, more than 
8,000 new cases were diagnosed during 2011 and 25 % of these were detected before 
50 years of age. The median age at diagnosis was 64 years. The prognosis has, 
however, improved during the last decade and the survival rate is now greater than 80 
%. Currently in Sweden, nearly 85,000 women are living as breast cancer survivors 
(2).  
The treatment of primary breast cancer consists of surgery, adjuvant radiotherapy 
(RT), and systemic medical therapy, e.g. chemotherapy and endocrine treatment. 
Furthermore, new effective targeted treatments have been introduced during the last 
decade, e.g. trastuzumab. However, post-operative, adjuvant RT still remains one of 
the cornerstones to reduce the risk for local recurrence. It has been utilized since the 
1930’s and at the end of 1940’s the first randomised, controlled trials of adjuvant RT 
were reported (3). With longer follow-up of these studies there was no survival benefit 
for the group receiving RT, instead a significant excess of non-breast cancer deaths 
was observed among these patients (4,5). Since then, several randomised trials and 
meta-analyses have shown a clinically significant reduction of local recurrences but no 
effect on overall survival. The beneficial effect of RT on survival was hampered by an 
increased risk of non-breast cancer deaths and analyses revealed that the largest cause 
was heart disease (6). Radiotherapy techniques and regimes have improved since these 
reports were published. Today, radiation exposure to the heart and lung is lower than 
they were in the earlier reports of the past. Thus, the latest meta-analysis and overview 
from EBCTCG in 2011 show a survival advantage for women receiving adjuvant 
radiotherapy compared to the unirradiated control group, i.e. the 15 year BC mortality 
decreased from 25.2 % to 21.4 % (absolute reduction 3.8 %). About one BC death was 
avoided by year 15 for every four recurrences avoided by year 10 (7). 
2:2 Clinical target volume definition in breast cancer 
The introduction of external megavoltage RT in the 1950’s led to improvements in 
target delineation and dose homogeneity, but also led to the incidental irradiation of 
deeper-seated tissues. Tolerance doses for normal tissue to therapeutic irradiation were 
defined by Emami et al in the 1990’s (8). In QUANTEC, Quantitative Analysis of 
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Normal Tissue Effects in the Clinic, we find the latest, updated overview and 
recommended dose/volume constraints (9). Computer tomography (CT) based RT 
planning in the 1980-90’s has improved target volume visualization and multi-field 
and 3-dimensional (3-D) conformal RT are now regularly used. By using 3-D RT 
planning and multi-field treatment, irradiation to normal tissue and organ at risk 
(OAR) can to some extent be avoided. Dose distribution, volumetric data, and dose 
volume histogram (DVH) are calculated. Presently, guidelines for RT are provided by 
The International Commission on Radiation Units and Measurements (ICRU). The 
volumes that must be identified prior to RT are defined in the ICRU report 29 and 
updated in report 50 (10,11). In breast cancer treatment, the clinical target volume 
(CTV), or planning target volume (PTV), is usually defined by the oncologist. The 
PTV takes into account patient movements, breathing motion, and inaccuracies related 
to therapy equipment and positioning. The definition of the CTV has, however, 
changed during the last decade after the introduction of 3-D dose planning. Previously, 
the definition was mainly made with respect to the bony anatomy. The CTV after 
breast conserving surgery is now defined as the remaining breast parenchyma with or 
without the loco-regional lymph nodes. The target volume after mastectomy is defined 
as the chest wall corresponding to the previous extension of the breast. The regional 
lymph nodes are defined as the ipsilateral axillary and supraclavicular nodes. 
Previously, the internal mammary lymph nodes (IMN) have in most of the Nordic 
Centres been included in the target volume. Currently, many centres have excluded RT 
to the lower IMN to avoid lung and cardiac toxicity. A recent meta-analysis in Lancet 
2005, however, demonstrated a benefit for RT after mastectomy in women with BC 
and positive lymph nodes and the majority of these women received RT to the lower 
IMN, i.e. in 21 of 23 trials (6). The randomised EORTC 22922/10925 trial, which tests 
the need for lower IMN irradiation, reports after three years of follow-up that RT to the 
IMN and medial supraclavicular nodes is well tolerated and does not impair the WHO 
performance status (12). Longer follow-up is, however, needed to determine excess 
cardiac toxicity and effect on overall survival. At ASCO 2011, Whelan et al reported a 
benefit for RT to the IMN in terms of reduction in distant recurrences, but also a small 
increase in rates of symptomatic pneumonitis (13). 
2:3 Radiotherapy-related heart and lung side-effects 
The aim of adjuvant RT is to eradicate left behind tumour cells without causing 
damage to the normal tissue, which can be described with models on Tumour Control 
Probability (TCP). Radiation therapy is also associated with side-effects in the treated 
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volume. By increasing the radiation dose to the target we will also increase the 
probability of damage to the surrounding normal tissue, which can be described with 
models on Normal Tissue Complication Probability (NTCP). Small difference in dose 
can have major biological effect (14).The therapeutic ratio is the ratio between the TCP 
and the NTCP (15,16). The radiotherapy schedules have been developed to maximize 
cure and to minimize the toxicity to normal tissue. 
Side-effects of RT develop mainly locally in the irradiated volume. The side-effects 
are classified as acute/early or late effects. Early effects may occur during or 
immediately after treatment in hours-days-weeks in rapidly proliferating tissue, e.g. the 
hematopoietic system as effects on blood cell counts, skin as erythema, and lung as 
acute pneumonitis. Late reactions may appear months or years after treatment, e.g. 
subcutaneous fibrosis, lung fibrosis (17), teleangiectasia, rib fractures (18), and 
brachial plexus neuropathia (19,20).The development of arteriosclerosis may be 
triggered by radiation exposure (21). Radiation-induced late cardiac effects, e.g. 
ischaemic heart disease, have been known for some decades, and have been studied in 
earlier projects. Women irradiated to the left breast during 1970-85 in the Stockholm 
Trial developed an increased risk of myocardial infarction (MI) compared to women 
treated for right-sided BC (22). Paszat and colleagues found similar results with higher 
risk for fatal MI among patients treated for left-sided BC during 1982-7 (23). 
Furthermore, Hooning found an increased risk in smokers and RT to tumours on the 
left side (24). 
2:4 Rationales of the studies  
Many women with BC have a long expected survival. Radiotherapy is often used in 
the adjuvant setting. The vast majority will live many years after RT as BC survivors. 
It is therefore of great importance to minimize the side-effects of RT, and to 
investigate the long-term effects in lung and heart.  
Papers I-III were intervention studies, in which an ipsilateral lung dose-volume 
constraint of V20 ≤ 30 % was applied. We aimed to reduce early symptomatic/ 
radiological pneumonitis and loss of pulmonary function compared with our previous 
work in this field Lind, (25-29). The chosen cut-off level was based on our previous 
finding that no case of moderate symptomatic pneumonitis (CTC grade 2; (30) was 
detected below this threshold (26).   
With respect to Paper IV: There are few data on the long-term effect of early radiation-
induced radiological lung abnormalities and functional changes. There are some 
indications that fibrosis is a continuous process (31) and that symptoms can be 
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develop/worsen late (32). Due to the scanty data, we therefore wanted to re-examine 
the women from our earlier cohort of 1994-8 to see if the earlier detected changes 
diminished or worsened. 
The term Radiation Induced Heart Disease (RIHD) was introduced in the 1960’s. 
Long-term follow-up in some trials had shown that RT could increase the risk of 
ischaemic heart disease (5). Due to changes in RT-techniques and planning, the doses 
to the heart are now generally lower than the doses in the earliest meta-analyses and 
trials on BC-irradiation. The relation between low dose radiation exposure and the 
development of radiation-related heart diseases is, however, still not fully known. A 
population-based case-control study with collaboration between Denmark, Sweden, 
and Oxford was therefore conducted and reported in Paper V. 
2:5 Definitions of the study populations 
Study I-III consisted of 88 patients referred to the Radiotherapy Department during 
2003-5 for adjuvant LRRT. In Study I, we report on RT-related radiological lung 
density changes and rates of clinical radiation pneumonitis in 66 of these patients. In 
Study II all 88 patients underwent chest X-ray and CT. Patients with radiological 
changes were compared with non-responders. Study III reported on pulmonary 
function tests (PFTs) in 64 of these patients.  
Study IV consist of seventy women from our previous cohort who received RT for BC 
between 1994-8 and were included in our earlier reports (26,28). These women were 
now re-examined with chest CT and PFTs after a median period of 11 years. Fifty-six 
women performed repeated PFTs. Eleven women abstained from participating. 
Study V was a population-based case-control study of major coronary events in 2,168 
women who received RT for BC between 1958-2001 in Sweden and Denmark. The 
study included 963 women with major coronary events and 1,205 controls. Patient data 
were obtained from hospital records and RT-charts and the different RT-techniques 
were reconstructed. 
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3. Radiobiology and fractionated radiotherapy 
Deposition of energy results in molecular damages in cells. The most important 
damages are double-stranded breaks in genomic DNA which cause cell death. Damage 
can also be inflicted indirectly in the cell by the ionization of water to hydroxyl 
radicals that cause single-stranded breaks. These result in sterilization, and loss of 
proliferative cells to sustain cell division. Proliferative sterilization is often referred to 
as cell kill. Cells that retain long-term proliferative ability are described as the survival 
fraction (33).  
The Strandquist plot: 
Magnus Strandquist was one of the first to describe the relation between the radiation 
dose necessary to achieve a certain biological effect and time during which the 
fractional treatment was in progress (Acta Radiol 1944). He introduced the log dose vs 
log time curves, viz. the Strandquist curves. Both the biological effect on the tumour as 
well as on the surrounding tissues were studied (34). 
The linear quadratic (LQ)-model: 
The Linear-Quadratic model was proposed by Douglas and Fowler in 1976 and it is 
based on a linear quadratic cell survival curve as a function of dose. It aimed to 
indicate quantitatively the biological effect of any RT-treatment, taking into account 
changes in dose-per-fraction or dose rate, total dose, and overall time (35).  
 
S  = e  ¯ (αd+ßd2) 
 
The Biological effective dose: 
The biological effective dose (BED) is useful to compare the effect of different 
fractionation schedules. The possibility of complete repair of sublethal damage 
between fractions is assumed. The term was introduced in 1989. 
 
BED = nd [1 + d/(α/β)]          
Number of fractions (n) 
Dose per fraction (d) 
α/ß defines the shape of the cell survival curve 
 
Early and late responding tissues: 
Radiobiological principles have gradually emerged over many years, and the 
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differences between late-responding normal tissues and early-responding normal and 
tumour tissues were clarified in the mid 1980’s. The tissue-specific α/β-ratio is 
reflected by the shape of the dose-response curve. Stem cells of late responding tissues 
have low α/β-ratios. 
Normal tissues are considered to have α/β-ratios around 3. Acute responding tissues 
have higher α/β-ratios and tumours are considered to have values around 10 Gy. Lung 
and heart have α /ß-ratios of 3 Gy and 2 Gy, respectively. 
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4. Pathogenesis and histopathology of radiation- 
induced injury to lung and heart 
Alveoli are the terminal portions of the bronchial tree and are responsible for the 
spongy structure of the lung. The wall of the alveoli is composed of a single layer of 
type I and type II pneumocytes, and endothelial cells. Type I cells cover 90 % of the 
alveolar surface and type II pneumocytes are the replicator precursors of type I cells. 
Type II pneumocytes produce surfactant, and a decrease of this production results in 
transudation of serum proteins into the alveoli. Between the alveoli there are thin 
layers of connective tissue and numerous capillaries (36,37). The primary function of 
the lung is to provide oxygen to and extract CO2 from the circulation. Radiation-
induced lung injury comprises two syndromes: 
Early phase, days/weeks, radiation pneumonitis: 
Radiation injury to epithelial and endothelial cells in the lung causes a cascade of 
events and involves the expression of inflammatory cytokines. The result is alveolar 
collapse and interstitial inflammation. This may happen days or weeks after irradiation. 
The cells show cytoplasmic swelling and degenerative changes and this causes 
increased capillary permeability and occlusion of the microvasculature by platelets, 
fibrin, collagen, and debris from dead cells. A series of open-lung biopsies from the 
field of irradiation in patients with clinical pneumonitis suggested lymphocytic 
infiltration as the dominant finding in the acute phase (38).The lymphocytic alveolitis 
is confined to the irradiated volume but there are suggestions of widespread 
inflammation also in the surrounding, un-irradiated lung tissue. In the last years, 
broncho-alveolar lavage (BAL) has been used in the diagnosis of RP (39). Rarely 
observations are made of bronchiolitis obliterans with organizing pneumonia (BOOP) 
(40). The latter entity could arise months after RT and can be localised outside the RT-
field. Mild RT-induced pneumonitis may be subclinical and reversible. 
Late phase, months/years, radiation fibrosis: 
Later, an organizing stage occurs, which includes the development of interstitial 
fibrosis. This phase has been widely documented in animal models. Pulmonary 
radiation reduces micro vessel density and lung perfusion, and promotes hypoxia. 
These effects may contribute to long-term damage, chronic inflammation, and late lung 
injury. This Radiation-Induced Lung Injury (RILI) may be regarded as a continuous 
progression of events. According to Graves, a hypothesis is that RILI is a result of an 
abnormal healing response in three phases: injury, inflammation, and repair (31). Pre-
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clinical studies suggest a role for transforming growth factor beta (TGF-ß), interleukin-
6 (IL-6), and other cytokines in the development of RILI (41). TGF-ß1 is the pro-
fibrotic cytokine that causes fibroblast differentiation, senescence, and collagen 
production. Patients with lung cancer and persistent high serum levels of TGF-ß before 
and during RT for lung cancer had higher risk of developing pneumonitis than those 
with lower levels (42). 
The main syndromes of RT Induced Heart Disease (RIHD) include inflammation and 
fibrosis. All structures can be affected. The most common manifestations are 
pericarditis, myocardial fibrosis, and coronary artery disease. Multiple studies in 
humans and laboratory animals have shown that irradiation can cause arteriosclerosis. 
Radiotherapy causes both acute and chronic changes in the heart tissues. The acute 
phase is characterized by a neutrophilic infiltrate in all layers of the heart within days 
after irradiation. Damage to the endothelial cells in arteries and capillaries can lead to 
luminal narrowing, perfusion defects, and ischemia (43,44). The adventitia is 
thickened and fibrotic in radiation-induced Coronary Artery Disease (CAD) compared 
with ordinary CAD (45). 
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5. Treatment of radiation-related injury to lung and 
heart 
Lung: 
Symptoms of RP are non-specific and include cough, i.e. non-productive or clear 
sputum, low grade of fever, dyspnoea, fatigue, and pleural chest pain. Lung 
auscultation may reveal crackles or a pleural rub. Chest X-ray changes are non-specific 
but typically confined to the irradiated volume. Airspace opacities are the most 
common finding. Pleural effusions or atelectasis are sometimes seen. Treatment with 
high-dose corticosteroids and antibiotics, e.g. tetracyclines, should start as soon as the 
diagnosis of RP is established. Steroids should be gradually reduced over weeks. If 
steroids are tapered too soon or too quickly, exacerbation of symptoms has been 
reported (46,47). Prophylactic administration of corticosteroids has been shown to 
decrease the physiological effect of radiation in mice. However, in humans this 
approach has failed to prevent the development of RP (48). No clinical benefit has 
been observed for treatment with steroids during the late stage of fibrosis (48,49). Pre-
clinical studies have assessed the effect of captopril, an angiotensin-converting enzyme 
inhibitor, and this drug appears to reduce RT-induced lung fibrosis in rats (50). The 
combination of pentoxyfylline, a methylxantine derivate, and vitamin E, reduces RT-
induced superficial and deep cervico-thoracal fibrosis, which earlier was considered 
irreversible in patients irradiated for breast or head and neck cancer (51,52). 
Amifostine, a sulfhydryl compound, believed to scavenge harmful free radicals that 
cause lung injury, has demonstrated inconsistent effects in clinical studies, and must be 
administrated concurrently with RT to be effective (53,54). Berberine, an alkaloid that 
exhibits anti-inflammatory activity and reduces the level of TGF-ß, has in clinical 
studies decreased RILI and improved pulmonary function in patients with NSCLC 
undergoing RT (55).  
Heart: 
There are no specific therapies or guidelines for treating RT-induced heart injury. 
Acute and chronic pericarditis is relatively uncommon but may sometimes occur. The 
patient may present with fever, pericarditis pain, dyspnoea, and tachycardia. Treatment 
includes the use of non-steroidal anti-inflammatory agents. A pacemaker can be 
indicated if the conduction system is affected. There are no specific therapies for 
radiation induced heart failure. The therapy should follow the College of Cardio / 
American Heart Associations Guide Lines according to Jaworski (56). The pro-
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phylactic treatment of risk factors has been discussed, e.g. hyperlipidaemia with 
statins. In case of flow limiting coronary artery disease, medical therapy or re-
vascularization can be indicated. The treatment of manifest radiation-induced coronary 
artery disease is not different to that of atherosclerotic origin (57). Screening for risk 
factors, especially in young patients, and treatment of diabetes, hypertension, 
hyperlipidaemia, and cessation of smoking should be recommended.  
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6. Factors influencing lung and heart tissue reaction 
to radiotherapy 
6:1 Radiotherapy-associated factors  
Variations in normal tissue reaction have been observed since the earliest day of RT. 
Factors related to the probability and severity of toxicity are type of radiation, total 
dose, dose per fraction, irradiated volume, irradiated site, and dose inhomogeneity. 
Toxicity from RT is in BC RT generally limited to the treated volume. The prescribed 
radiation dose to the breast or chest wall in BC RT is higher than the tolerance dose of 
lung.  
Dose-effect relations in single fraction total thoracic irradiation: 
The single fraction threshold dose for radiation pneumonitis starts at 7.5 Gy in total 
thoracic irradiation according to Dyk et al. They observed a steep dose-response 
relation that rose from 5 % to 50 % complication probability with an elevation of the 
single dose from 8.2 to 9.3 Gy (58). 
Dose-effect relations in fractionated total thoracic irradiation: 
Emami et al have compiled tolerance data for organs at risk and proposed that a total 
dose to the thorax of 24.5 Gy would lead to a 50 % probability of pulmonary 
complications in 5 years (tolerance dose TD 50/5) with conventional fractionation of 
daily 1.8-2.0 Gy 5 days a week. QUANTEC recommends that the volume fraction of 
the lungs that exceeds 20 Gy should be restricted to 30 %. This will give a probability 
of symptomatic pneumonitis of less than 20 % in  standard clinical fractionation (9). 
Effects according to fraction dose for irradiation to partial lung volumes: 
Overgaard and co-workers reduced the fractions and increased the dose from 2 to 3 Gy 
in post-mastectomy RT between 1978 - 81. The incidence of both RP and lung fibrosis 
increased among women treated with this higher fraction dose compared with a 
conventional fraction schedules (59). There are also data from randomised studies 
comparing hypofractionated RT with doses > 2 Gy to conventional RT. Whelan et al 
presented 10 year results of comparing 2.66 Gy to 42.4 Gy with conventional 
fractionation of 2 Gy to 50 Gy. There was no difference in normal tissue complication 
or increase in toxic effects in the group receiving hypofractionated RT. Other studies, 
START-A and START-B (Standardisation of breast radiotherapy), compared 
conventional doses with 3.2 Gy to a total dose of 41.6 Gy, 3 Gy to 39 Gy, and 2.66 Gy 
to 40 Gy. No difference in cosmetic outcome compared to conventional fractionation 
was detected (60).  
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Dose-effect relations in fractionated cardiac irradiation:  
Pericarditis was the chosen heart toxicity end-point in the Emami paper (8). 
Information from whole heart irradiation comes mostly from patients treated for 
Hodgkin’s disease, whilst partial volume irradiated data come from post-operatively 
treated BC patients. A total dose of 40 Gy to the entire heart leads to a 5 % probability 
of heart complications in 5 years (TD 5/5). QUANTEC recommends that the volume 
fraction of the heart that receives ≥ 10 Gy should be restricted to 25 % for whole heart 
irradiation. The latter constraint will lead to a risk for long-term cardiac mortality of  < 
1 %  (16).  
6:2 Intrinsic factors 
Individual differences in radiosensivity: 
There is a significant individual variation in radiosensivity among patients. This is 
likely due to genetic differences (14,61). Patients with ataxia telangiectasia, a rare 
hereditary disease, have a high incidence of malignancies and both the tumour and 
normal tissue are exquisitely sensitive to ionizing radiation in these individuals (62). 
Results from studies identifying genetic factors associated with radiosensivity would 
help to predict which patients have increased risk for complications (63,64). RAPPER, 
Radiogenomics: Assessment of Polymorphisms for Predicting the Effect of 
Radiotherapy, is a large multicenter study addressing this issue (65). 
Age:  
Various results have been published concerning the influence of age on RT-induced 
toxicity. There are data from a Danish study with 8 years of follow-up after treatment 
for Hodgkin’s disease. Patients with low age (< 30 year) at therapy had more 
restrictive lung disease in the follow-up (66). Other previous studies have, however, 
reported an increased risk of pneumonitis in breast cancer patients of advanced age 
(27,28). Gagliardi et al (67), Kahan et al (68) also found a higher risk of lung 
complications with increased age in BC patients. The functional reserve of the lung is 
age dependent and decreases in the elderly as the elasticity in the lung decreases, 
which reduces the ability to compensate for RT-induced injury. In contrast, Hardman 
et al found no association between age and pulmonary injury in BC patients (69). In a 
literature-based meta-analysis in 2012, 4/31 studies including BC patients, Vogelius 
and Bentzen found a significant risk for pneumonitis in older patients, i.e. 57 to 70 
years of age (70).  
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6:3 Extrinsic factors   
Pre-existing lung and heart disease: 
Patients with pre-existing lung disease and poor pulmonary function have a low 
capability to compensate for radiation injury (71). It is not known whether the lung 
tissue is more sensitive to RT in this group. Poor performance status was another 
potential risk factor for RP in the above mentioned meta-analysis by Vogelius and 
Bentzen (70).  
Pre-existing ischaemic heart disease is a risk factor for RT-induced IHD  (72,76). 
Other co-morbidities: 
Vascular and connective tissue diseases are a heterogeneous group of diseases which 
have been considered a relative contraindication for RT due to sporadic reports of 
increased treatment toxicity (73,74). Li et al reported results on seventy-three patients 
with different connective tissue diagnoses. They found no difference in acute side-
effects compared to a normal population but more late complications (75).  
A history of ischaemic heart disease, hypertension, or diabetes and high BMI increase 
the risk for major coronary events after RT according to King et al (76). 
Atherosclerosis: 
The development of atherosclerosis can be triggered by radiotherapy and it is a risk 
factor for RT-induced IHD (77) . 
Smoking: 
Smoking and poor pulmonary capacity at baseline may predict for an increased risk of 
pneumonitis. 
Smoking decreases the diffusions capacity of lung due to pulmonary vasoconstriction 
(78,79). Smoking may, however, protect both tumour and normal tissue from acute 
radiation effects (80,81,82). The suggested mechanism is that smoking suppresses the 
local inflammatory reaction in the lung (83). However, in a Danish study in patients 
with Hodgkin’s disease smokers had reduced lung function compared to non-smokers 
8 years after thoracic irradiation (66). 
Radiotherapy and smoking had an additive effect on the risk of myocardial infarction 
in BC patients (84). 
Concurrent chemotherapy: 
It is known that certain chemotherapeutic agents have synergistic interaction when 
given concurrently with RT. A number of cytotoxic drugs have been investigated, on 
this matter, both in vivo and in vitro, e.g. methotrexate, bleomycin, doxorubicin, 
cyclophosphamide, docetaxel, and gemcitabine. They are all known to cause 
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pulmonary toxicity by local inflammation. Taghian et al have reported an increased 
incidence of RP in women treated for BC with chemotherapy combinations including 
paclitaxel, concurrently or sequentially, with RT (85, 86). Anthracyclines significantly 
added to the elevated risks of congestive heart failure and valvular disorder from 
mediastinal RT in Hodgkin’s disease (87). However, most data on this topic are based 
on experience from other diagnoses than breast cancer (48, 88-90). 
Concurrent tamoxifen, aromatase inhibitors: 
Tamoxifen has been reported to influence the risk of post-RT fibrosis. Some studies 
suggest that tamoxifen induces secretion of TGF-ß that effects the development of 
fibrosis (91).  
Aromatase inhibitors, viz. letrozole, and RT have been evaluated in a randomized trial 
in BC and the combination has been considered to be safe with respect to short-term 
toxicity. There are, however, no long-term data and a subtile radiosensitizing effect 
may theoretically show up as chronic changes with longer follow-up (92).  
Concurrent trastuzumab and new targeted therapies: 
Trastuzumab is a humanized monoclonal antibody directed against the growth-factor-
receptor Her 2neu, and it is used as adjuvant therapy in BC patients with Her 2neu 
positive tumours. Halyard and colleagues have studied trastuzumab alone or in 
combination with RT and they found no increase in skin toxicity or rate of pneumonitis 
(93). 
Bellon et al reported an 8 % rate of RP in a small study of 26 patients treated with 
concurrent trastuzumab and RT (94). A French multicenter study on the potential 
synergistic effect of concurrent RT and trastuzumab, showed that women who were 
treated with weekly concurrent trastuzumab and RT developed a decrease of the left 
ventricular ejection fraction (LVEF) (95).  
Pertuzumab, a recombined humanized monoclonal antibody that targets the 
extracellular dimerization domain for Her2 is not yet used clinically in the adjuvant 
setting. 
Trastuzumab emtansine, T-DM1 monoclonal antibody with the cytotoxic agent 
emtansine, has been tested for metastatic Her2 neu positive breast cancer, but it is not 
in clinical use in the adjuvant setting. Both of the latter drugs should be evaluated for 
added toxicity if they are combined with RT in the future. Other examples of targeted 
therapies tested in BC are inhibitors of angiogenesis, e.g. bevacizumab and 
tyrosinkinase inhibitors (TKI). These inhibitors may affect the cardio-vascular function 
but have not been evaluated in combination with adjuvant RT for BC. Data on TKI-use 
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obtained from renal cells carcinoma patients indicate a relation with LVEF decline and 
high-grade hypertension (96). 
In conclusion, the addition of targeted drugs to RT must be monitored for potential 
short- and long-term side-effects (97, 98). 
6:4 Summary of literature review 
Radiotherapy has been used for over a hundred years. During the last decades, RT-
associated late side-effects have been more frequently discussed as the number of 
long-term survivors increase due to early diagnosis and the introduction of many new 
effective adjuvant therapies. Thus, both short and long-term effects of RT are 
becoming increasingly important. The side-effects of RT to lung and heart have been 
investigated in several randomised and observational studies. These trials have, 
however, often studied different end-points and the grade of toxicity has not always 
been reported. Radiotherapy to the IMN is less frequently recommended today and this 
probably reduces radiation doses both to lung and heart. We need more data on the 
interaction between clinical co-variates, e.g. cytotoxic treatment and targeted therapies, 
and post-op radiotherapy, as the clinical practice frequently changes with the 
introduction of new drugs. Baseline measurements should be gathered before start of 
any treatment. Results from studies aiming at identifying genetic factors associated 
with radiosensivity will also be of great value for the clinician.       
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7. Radiotherapy-related radiological changes with lung 
with V20 lung constraints  
7:1 Introduction 
Since 1896, one year after Wilhelm Conrad Roentgen’s discovery of the X-rays, 
radiotherapy has been given to very many women with BC (99).  
The lung is one of the most radiosensitive and vitally important organs of the body. A 
report on respiratory side-effects in a patient treated for tuberculosis with irradiation of 
the thorax was published as early as in 1898. Tyler and Blackman also described 
clinical and radiographical changes of RT-induced lung damages in 1922 (100). 
The temporal distinction between two separate types of radiation-induced lung injury 
was made as early as in 1925. Today, the development of both pneumonitis and 
radiation fibrosis is followed in patients who undergo thoracic irradiation where large 
part of the lungs are irradiated, e.g. in lung or oesophageal cancer patients. The 
severity of the RT lung injury can for some tumour types vary from a mild cough, 
dyspnoea, and low-grade fever to severe impairment of the respiratory function.  
The risk of acute and chronic side-effects is most importantly influenced by total dose, 
dose per fraction, and volume of incidentally irradiated lung. Acute radiation 
pneumonitis occurs after weeks up to 6 months following treatment and may be 
reversible. One of the earliest clinical reports of this entity was presented by Groover et 
al in 1923 (101). The term radiation pneumonitis was introduced by McIntosh and 
Spitz in 1939 (102). Ten years later Fried and Goldberg published the first report on 
late lung tissue response (103). Symptoms of acute radiation pneumonitis can be 
similar to symptoms of infection or drug-induced pulmonary toxicity. These 
differential diagnoses most, thus, also be taken into account (104). 
RT-induced pneumonitis can also be subclinical and reversible without any sequelae.  
However, late effects with dyspnoea and impaired daily function months to years after 
thoracic irradiation can be signs of pulmonary fibrosis. Furthermore, the pulmonary 
circulation can be affected by severe lung fibrosis and lead to right-sided hypertension 
and cardiac failure. 
7:2 Previously reported outcome data 
The incidence of RT-induced lung injury is about 5-15 % in irradiated breast cancer 
patients, according to Marks (53). Eleven BC studies were reviewed in this publication 
and the three largest studies included over a thousand patients each (17, 82, 105-113). 
The rate of pneumonitis varied between 1-19 %. Many of these, reports, however, 
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originate from the late 1990’s when various definitions of CTV and less sophisticated 
treatment RT-techniques were used. The use of different end-points for lung toxicity in 
the studies also makes the results difficult to compare. Some studies evaluate clinical 
symptoms alone and others include radiological methods, e.g. chest X-ray, CT, 
SPECT, or measurement of respiratory function. Clinical symptoms, e.g. cough and 
dyspnoea, are often non-specific and can be caused by other factors than RT, e.g. 
pneumonia, cardiac failure, anaemia, or metastatic disease. 
Another obstacle for systemic overviews of RP studies is the lack of consensus on the 
definition of symptomatic pneumonitis and grading of severity. Furthermore, some 
studies define RP as an early event and others as a late phenomenon (70).  
Our interest in this field originally stems from a clinical observation and a 
retrospective review of 177 BC women who where treated with RT during 1991-3. We 
checked the patients’ records for notes on a history of respiratory complaints or signs 
of radiation pneumonitis at the women’s pre-scheduled follow-ups 1, 4, and 7 months 
post-RT. The cases were classified in three groups (no reactions, slight reactions, or 
moderate reactions impairing daily function and treated with corticosteroids). The old 
radiotherapy techniques were reconstructed on CT slices of 10 model patients. The 
percentage of ipsilateral lung volume receiving more than 20 Gy was calculated and 
V20 was 50 % for the treatment technique used after mastectomy (25, 26). About 10-15 
% of patients complained of lung symptoms that were recorded as caused by RT. 
We therefore continued and prospectively studied short-term pulmonary side-effects 
following RT in 475 BC patients treated with RT during 1994-8. The incidence of 
severe post-irradiatory complications among patients treated with loco-regional RT 
including the IMN was 10 %. Moderate pulmonary complications were rare among 
women treated with local RT only. The mean irradiated ipsilateral lung volume 
receiving more than 20 Gy was larger among women diagnosed with clinical and/ or 
radiological side-effects (25,26). Advanced age and reduced pre-treatment functional 
level were independently associated with higher rates of post-RT pulmonary 
complications in our previously followed cohort of BC women.  
Based on the outcome data from the above cited and previously published paper, the 
present studies were conducted with the goal to individualise treatment planning in 
order to reduce the rate of pulmonary complications (114). 
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7:3 Summary of Study I 
In this part of the intervention study, our aim was to reduce the rates of clinical and 
radiological pneumonitis by applying a lung dose volume constraint in adjuvant RT for 
breast cancer.  
Patients and methods:  
Sixty-six women, who were referred to our Radiotherapy Department for adjuvant RT 
during 2003-5 were included. They underwent treatment planning aimed at avoiding 
doses in excess of 20 Gy to more than 30 % of the ipsilateral lung volume, i.e. V20 ≤ 30 
%. 
Data on potential confounding factors for developing radiation pneumonitis were 
collected at baseline, e.g. history of pulmonary or cardio-vascular disease, smoking 
habits, reduced functional level, and pre-RT chemotherapy. Concomitant use of 
endocrine- or trastuzumab treatment during RT was registered. 
The patient’s were prospectively followed for symptoms of radiation pneumonitis 1, 4, 
and 7 months post-RT. Cases of pneumonitis were graded according to modified CTC-
criteria (version 2.0) (115). 
In each patient, a chest CT was performed 4 months post-RT and the findings were 
compared to the patient’s treatment planning CT. 
Computer tomography is based on the X-ray principal: When X-rays pass through the 
lung they are either absorbed or attenuated at different levels, which creates a matrix or 
a profile of X-ray beams of different strengths. 
New lung abnormalities on post-RT CT at 4 months were analysed with a CT-adapted 
modification of Arriagada’s classification (Fig. 7:1) (116). According to this semi-
quantitative classification, the patient’s lung should be divided into three regions; 
apical-lateral (A-L), central-parahilar (C-P), and basal-lateral (B-L). 
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Fig. 7:1. Division of the lung into 3 regions according to Arriagada: apical-lateral 
(black area), central-parahilar (striped area) and basal-lateral (white area). 
 
Furthermore, increases in density are graded as 0 (no change), 1 (low opacity in linear 
streaks), 2 (moderate opacity), 3 (complete opacity). The highest density grade of each 
region is added together. A total score of 1-3 represents a mild radiological reaction, 
while scores of 4-9 represent moderate to severe reactions.  
The individual abnormal lung subvolumes (Fig. 7:2) were contoured and measured and 
the mean doses were calculated.  
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There was a strong interrelation among all the studied dosimetric factors. 
Discussion:  
Modern radiation treatment planning aimed at minimizing the incidentally irradiated 
lung volume resulted in few cases of short-term lung symptoms. The average 
ipsilateral V20-value in symptomatic women, i.e. 29 % was higher than in 
asymptomatic cases. The majority of cases developed mild radiological changes on 
CT, but these were, however, generally not accompanied by symptoms. It may be 
warranted to follow these mild abnormalities a later time point to rule out the 
development of chronic symptoms. 
7:4 Summary of Study II 
Patients and methods: 
In this part of our project, 88 women with BC who had undergone post-operative RT 
with a lung dose volume constraint, i.e. ipsilateral V20 ≤ 30 %, were evaluated for 
changes on chest X–ray (Fig. 7: 3) and effects on Quality of Life (QoL) 4-5 months 
after treatment. The post-RT radiological changes were compared with the outcome in 
our previous trial of 137 irradiated women when a pre-planned lung dose-volume 
constraint was not used (27,28). Furthermore, the outcome on chest X-ray exams in the 
present series was compared to findings on chest CT. The semi-quantitative Arriagada 
classification was used for the analysis of radiological changes, which takes into 
account number of affected lung regions and highest grade of density increase (116).  
                             
 
Fig. 7:3.   Example of grade 2 abnormalities in all 3 regions of the right lung on chest 
X-ray.      
 
  22
To study effects on QoL we used the European Organisation for Research and 
Treatment of Cancer (EORTC) form QLQ-30 and the EORTC QLQ-BR-23 (117, 
118). The patient filled out the forms prior to and 4 months after RT. We selected to 
analyse items related to pulmonary symptoms such as physical functioning, role 
functioning, social functioning, fatigue, pain, dyspnoea, insomnia, and future 
perspective. A high score on the global health status/functional scale represent a high/ 
healthy level of function. In contrast, a high score on the symptom scale reflects a high 
level of symptoms/ problems. 
Result: 
Only one patient developed moderate lung symptoms, which were treated with 
corticosteroids, whereas six patients were diagnosed with mild symptomatic radiation 
pneumonitis. No relation was found between symptomatic and radiological RP on 
chest X-ray or CT in this series. There was a significant reduction of moderate-severe 
radiological RP on X-ray for the treatment technique LRRT+IMN compared to our 
earlier trial (p<0.001). However, there was no difference between the old and present 
series for the treatment technique where the IMN were excluded. We found no 
correlation between any dosimetric factors or the studied co-variates and radiological 
changes on chest X-ray in multivariate analysis. In the present series, there was no 
agreement between X-ray and CT as diagnostic tools for radiological RP, which 
probably was due to the small lung volumes that were affected. 
Chest CT was, thus, a more sensitive method to detect small affected lung volumes 
compared with X-ray. The dosimetric factor V13 was most strongly and independently 
related with radiological changes on CT. Quality of Life was very little affected by RT 
in this treatment series. Due to pre-RT chemotherapy the patients started with high 
scores of fatigue. Role functioning, social functioning, and future perspective were 
improved 4 months after RT compared to baseline.  
Patients treated with high V13 appeared, however, not to recover equally well, e.g. 
difficulties to take short walks, and this association was also reported when the patient 
rated their overall total QoL during the last week. Furthermore, there was no effect of 
RT on physical functioning, pain, or dyspnoea in this series.  
Discussion: 
The results of this study indicate that the used dose volume constraints significantly 
reduced moderate-severe radiological RT on chest X-ray compared to our previous 
study. The lung changes could not always be detected on chest X-ray and were also 
less frequent and limited on chest CT. Ipsilateral V13 was correlated with occurrence of 
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radiological RP on CT. Co-variates such as smoking, age, chemotherapy, endocrine - 
or trastuzumab therapy did not influence this outcome. There were, however, few 
events in this study, which hampers its ability to detect small-moderate statistical 
relations. 
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8. Radiotherapy-related changes in pulmonary 
function with V20 lung constraints 
8:1 Introduction 
Pulmonary function tests (PFTs) must be performed under standardized conditions 
(119). The tests are dependent on the patient co-operation. The methods are 
inexpensive, reproducible, and widely available. The most common used 
measurements are vital capacity (VC); the maximum volume of air that can be expired 
after maximum inspiration, forced expiratory volume in 1 second (FEV1); the volume 
of air exhaled during the first second of a forced expiration manoeuvre is started from 
the level of total lung capacity, diffusing capacity of carbon monoxide (DLCO); the 
ability of gas to diffuse across the alveolar-capillary membranes.  
8:2 Previously reported outcome data 
Our previous study evaluated PFTs 5 months after RT that did not include a lung dose 
volume constraint in 144 women with BC in comparison to a pre-RT examination. 
Patients treated with LRRT experienced a mean reduction of both DLCO and VC. In 
the 9 % of women who developed moderate symptomatic pneumonitis there was a 
significantly larger mean paired reductions in VC than in asymptomatic patients (29). 
Surprisingly, there was a mean increase in diffusions capacity by 7 % (p=0.004) 
following RT that probably was due to transient toxicity of the chemotherapy that had 
been administered prior to RT. 
Vernbanck et al have studied small airways in BC patients before and after RT to 
examine whether the function are normal at baseline before RT (120). The study group 
consisted of non-smoking, middle age women with no history of respiratory disease. 
They were compared with healthy controls and were found to have normal values 
before RT. 
Jaén and co-workers reported data on short-term and long-term changes in pulmonary 
function after LRRT in 39 women with follow-up after 6, 12, and 36 months. All PFTs 
decreased at 6 months, however, all except DLCO returned partially to pre-treatment 
values after 12 months (121). Longer follow-up for 7 years showed a decrease in the 
first 2 years but recovery to baseline values in the long-term. The diffusion capacity 
was reduced for 24 months before returning to normal. This study also looked at 
changes in perfusion and ventilation scintigraphy data that showed a similar pattern as 
for the DLCO abnormalities (122). 
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8:3 Summary of Study III 
Patients and methods:  
In this study we investigated changes in PFTs and short-term symptomatic radiation 
pneumonitis (RP) in 64 women. Their mean age was 55 years. The ipsilateral lung 
dose volume constraint V20 < 30 % was applied in the treatment planning. Data on 
potential confounding factors for pulmonary complication were collected prospectively 
as previously described. The study population had no major medical conditions and 
good functional levels at baseline.  
Patients were monitored 1, 4, and 7 months after RT for respiratory symptoms. 
Pulmonary function tests were performed before and 5 months after completion of 
treatment. 
Chemotherapy was concluded 3-4 weeks before RT. The most common regime 
consisted of FEC (5-fluorouracil 600 mg/m2, epirubicin 60-75 mg/m2, and 
cyclophosphamide 600 mg/m2, d 1q 3 weeks x 6). Concurrent chemotherapy was 
never given. The outcome was compared with our previous treatment series (29).  
Result: 
In a few cases we had to accept a somewhat higher V20 than 30 % due to the patients’ 
anatomy. There was, however, a statistical significant reduction in mean V20 (35 % vs. 
26 %) and V30 (24 % vs. 16 %) compared with our previous trial. We found four mild 
and one moderate cases of symptomatic RP, which was a lower frequency than in our 
previous report (p<0.001). The mean changes in VC and DLCO appeared lower than 
in our previous report in which constraints was not used.  
We found no correlation between the evaluated co-variates and PFTs changes, i.e. 
DLCO and VC, except for pre-RT chemotherapy and less post-RT DLCO changes. 
Again, this was probably influenced by low baseline DLCO-values after chemotherapy 
prior to start of RT, as cyclophosphamide is known to induce local inflammation in the 
lung parenchyma (88).  
Tamoxifen is reported to influence the risk for post-RT fibrosis (91). We have 
previously reported that concomitant tamoxifen during RT has no influence on VC and 
DLCO changes (29). However, when we now re-analysed the data for women who 
received LRRT including the IMN in our earlier study and included individual 
dosimetric data we found a possible relation between tamoxifen and VC-changes. 
Discussion: 
Radiation pneumonitis was rare when lung dose volume constraints and 3-D planning 
were used. The lack of relation between dosimetric factors and reduction in PFTs in 
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this present trial may be due to the limited study size. Another cause could be the 
observed small mean changes in VC and DLCO with the used lung dose volume 
constraints. Ideally, PFTs should be performed before start of any BC therapy, as the 
diffusion capacity of the lung is affected by chemotherapy. In this study, the most 
commonly used chemotherapy was FEC. Both cychlophoshamide and methotrexate 
are known to cause pulmonary toxicity by local inflammation. In the re-analysis of our 
earlier cohort of 144 patients with the inclusion of individual dosimetry data, 
tamoxifen intake appeared to increase post-RT VC-changes. 
8:4 Other techniques for functional studies 
Single photon emission computed tomography (SPECT) is used to map organ function 
and metabolism. The combination of CT and SPECT can show the exact localization 
of non-functioning tissue and it is a very sensitive method for monitoring radiation 
lung damage (123-127). 
Ma and colleagues investigated the association between RT-induced changes in lung 
tissue density and global function in lung, lymphoma, and breast cancer patients. They 
found a weak quantitative association between the degree of increase in lung density as 
defined by CT and the percentage reduction in PFTs (128). They also included SPECT 
in their study with the belief that SPECT imaging would provide a more physiological 
assessment of the lung function than CT alone. 
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9. Radiotherapy-related long-term functional and 
radiological pulmonary changes       
9:1 Introduction 
Radiotherapy is known to cause late lung side-effects and from 6-8 months after RT 
fibrosis may develop. 
There are relatively few reports on the long-term consequences of RT on the 
respiratory function in BC patients (122,129-133). Some of the most important earlier 
publications are listed in Table 2 of Paper IV. 
A few of these reports suggest that lung function changes after irradiation for BC 
follows a biphasic pattern. This consist of an early reaction with a maximum after six 
months and partial recovery after one year followed by a late progressive worsening 
after 8-10 years. 
The purpose of Study IV was to assess late pulmonary side-effects in women irradiated 
with LRRT without a pre-planned lung dose volume constraint at our Department 
between 1994-8, and to compare their present lung function with the their pre-RT 
respiratory status. 
9:2 Summary of Study IV 
Patients and methods: 
We re-examined women from our earlier cohort of 475 patients with Stage I to Stage II 
node positive BC referred to the Radiotherapy Department at Stockholm Söder 
Hospital for adjuvant RT during 1994-8. Computer tomography was performed in 70 
of these women after a median of 11 years after RT. Twenty-nine of the women had 
undergone the pre-RT, the 4 months post-RT, and the late chest CT examinations. 
Fifty-six women performed the long-term repeated PFTs follow-up. 
Data on potential pre-disposing factors for RP, i.e. history of cardiovascular- or 
pulmonary co- morbidity, smoking habits, and reduced functional level, were collected 
both before start of RT and at the long-term follow-up. To evaluate the radiological 
lung changes on CT we used the previously described semi-quantitative CT-adaption 
of the Arriagada classification (116).  
Results: 
The long-term follow-up showed a 10-15 % reduction of the median matched VC, 
TLC, and FEV1 measurements compared to pre-RT levels. Measurements of DLCO 
increased after 11 years, which was probably due to a transient effect of pre-RT 
chemotherapy. The median matched percentage of the predicted DLCO value at 11 
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years was, however, only 86 %, which suggests a chronic therapy-induced reduction 
also of this metric. Changes on CT visible at 4 months after RT were still detected after 
11 years and appeared similar at this follow-up. We found a correlation between V20 
and long-term CT-changes but not with VC-changes. 
Discussion:  
Similar lung abnormalities on CT as after 4 months post-RT were detected at a follow-
up after 11 years. The median percentage of the predicted VC, FEV1, and TLC were 
lowered 10-15 %. Most of the women received adjuvant chemotherapy pre-RT. It 
would have been of interest to measure the baseline values before start of adjuvant 
chemotherapy as this affected the pre-RT DLCO results. Fibrosis is an on-going 
process according to some researcher. To follow this cohort of women for additional 
years would perhaps answer the question if the lung changes will diminish or increase 
with time. 
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10. Radiotherapy-related heart disease 
10:1 Introduction 
There are many pieces of evidence in the literature that RT may be cause late 
morbidity to the heart (23, 134-139).  
The law of Bergonie and Tribondeau was developed in 1906 by two French 
radiobiologists. 
It states that the radiosensitivity of cells is directly proportional to their reproductive 
activity and inversely proportional to their degree of differentiation. According to this 
hypothesis, the heart is considered to be a radioresistant organ. In 1957, Pearson, 
however, reported that intimal proliferation secondary to chest wall irradiation might 
have caused myocardial infarction in two women (140). As more case reports 
followed, Fajardo and Stewart started experimental studies in this field in the late 
1960’s. These studies showed that the heart and vessels are sensitive to RT (141). High 
incidences of coronary artery disease were also observed in patients who as children or 
adolescents were irradiated during 1960-1991 for Hodgkin’s disease (142). 
Furthermore, irradiated heart volume and dose to heart are related with an increased 
risk of death due to ischaemic heart disease in patients treated for Hodgkin’s disease 
according to Eriksson et al (143). Cusack’s overview, which was published 1987 and 
updated 1994, demonstrated an excess of cardiac deaths among women irradiated for 
BC compared with women only treated with surgery (5,144). A study of 55,000 
women diagnosed with BC in Sweden during 1970-85 showed an increased risk of 
death from myocardial infarction among women with cancer of the left breast 
compared to the right side (145). An updated analysis of this study in 2003, with 
women diagnosed until 1996 and including 90,000 cases, found that the mortality ratio, 
left vs right (146), for all cardiovascular diseases was 1.04 (95 % CI: 1.00-1.09). 
A number of large randomised trials have shown increased risk of cardiac mortality 
after BC irradiation (6,147). Even the effect of low doses of environmental and 
occupational radiation exposures have been studied and shown to increase the risk for 
myocardial infarction (148, 149). 
More than 30 different breast cancer RT regimes have been used in Sweden since the 
1950’s. Cardiac doses varied between < 1 Gy to 24 Gy for the heart and between < 1 
Gy to 46 Gy for the LAD coronary artery (150). The different anatomical structures in 
the heart may have different radiation tolerances (151,152). Increased knowledge on 
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the dose-response relationship for the development of ischaemic heart disease would 
be of great importance in BC RT-planning. 
10:2 Summary of Study V 
Patients and methods: 
A population-based case-control study was conducted in Denmark and Sweden with 
women treated with external RT for invasive BC during 1958-2001. In Sweden, 
women younger than 70 years and living in Stockholm were considered for the study. 
Major coronary events were defined as the diagnosis of myocardial infarction 
according to the International Classification of Diseases, 10 th Revision (ICD-10 codes 
121-124); coronary revascularization, or death from ischemic heart disease (ICD-10 
codes 120-125). Events of angina alone were not included. Women without a 
histological diagnosis of BC were excluded. Other exclusion criteria were previous 
cancer (apart from non-melanoma skin cancer) and previous RT to the thoracic area. 
All other women who received RT were cross-matched with the nationwide registries 
of diagnosis at time of hospital discharge and cause of death. Ninehundred and sixty-
three cases and 1,205 controls were included in the analysis. 
Data on the medical history at time of BC diagnosis and treatment of BC were 
abstracted from hospital oncology records. Each individual RT-chart including 
photographies of treatment fields and dose-plans were copied. Virtual simulation and 
planning based on CT (for a few regimes manual planning) were used to reconstruct 
each RT-regime on the CT of a woman with a typical anatomy (150,153). Dose 
volume histograms were calculated for the whole heart and for the left anterior 
descending coronary artery for the different regimes. Equivalent dose in 2 Gy fractions 
(EDQD2) was calculated from the dose volume histograms (21): 
 
nd((d+ α/β)÷(2+ α/β))  
n=number of fractions  
d=dose to the heart per fraction (in Gy)  
α/β: 2 
 
Event rate ratios (RR) were estimated using conditional logistic regression with 
stratifications for each matching factor.  
Results: 
Women irradiated for left-sided tumours had higher rates of major coronary events 
than women undergoing irradiation for right-sided cancers (p=0.002). There were, 
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3.2 percentage points. For women with one or several pre-existing cardiac risk factors 
both the risk at baseline and the absolute increase in risk are elevated. 
Discussion:  
We found that rates of major coronary events increased linearly, without a threshold, 
with incidental irradiation of the heart by 7.4 % per Gy. The percentage increases per 
unit were similar for women with or without pre-existing cardiac risk variables, which 
suggests that the absolute increases in risk for a certain dose to the heart were larger for 
woman with pre-existing risk factors.  
Almost all of the women in this study were treated before 3-D planning was in use. 
Furthermore, few of the women were younger than 40 years of age at the time of 
treatment and caution is therefore needed when applying our results on this younger 
age group.  
In our cohort, there were also few women treated with antracyclines, taxanes, or 
targeted therapies, which all are known to affect the heart by themselves.  
Our results point out the importance for the use of RT-techniques where the heart is 
excluded from the radiation fields. It is therefore important to outline both the heart 
and the coronary arteries as OAR in the dose planning process and to minimize doses 
to these volumes. It is also necessary to weigh the pros and cons for the individual 
patient when adjuvant therapies are selected.  
Today, there are alternative RT-methods available which reduce the incidental dose to 
the heart. Respiratory gating delivers the radiation in the breathing phase when the 
heart is out of the radiation field (154,155). The patient can also be treated in a prone 
position (156-158). Some centres have used Intensity Modulated Radiation Therapy, 
IMRT, to lower dose to the heart. The latter technique may lower the dose to the heart 
but it involves more radiation fields and larger volumes of normal tissue are therefore 
exposed to low dose radiation (159,160). Proton therapy is another alternative 
technique for lowering dose to heart, but no randomised study has yet been performed 
with this modality in BC (161,162). 
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11. Conclusion of Studies 
Study I 
Adjuvant BC with modern treatment planning and the incorporation of an ipsilateral 
lung dose volume constraint of V20 < 30 % resulted in few cases of short-term 
symptomatic radiation pneumonitis. The ipsilateral V20 was higher in symptomatic 
compared to asymptomatic women, 29 % vs. 24 % (p=0.04). The majority of cases 
developed, however, mild radiological changes on chest CT. There was a trend for 
relation between V30 and moderate-severe density changes on chest CT (p=0.08). The 
mean dose in lung subvolumes with radiological density abnormalities in affected 
patients was 37 Gy (SEM: 1.5). This was significantly higher than the average 
ipsilateral MLD of 13 Gy (p=0.001). The analyses of the relation between the different 
dosimetric factors, i.e. ipsilateral V13, V20, V30, and MLD, and other co-variates and the 
studied end-points with multivariate modelling were hampered by the study sample 
size and relatively few events. 
Study II 
Adjuvant BC RT with modern treatment planning and the incorporation of an 
ipsilateral lung dose volume constraint of V20 ≤ 30 % resulted in fewer cases of short-
term radiological changes on chest X-ray compared with our previous study. There 
was also a statistically significant reduction in average V20 (35 % vs. 26 %) and V30 
(24 % vs. 16 %) in the present series compared with our earlier trial. The lung changes 
in the present trial could not always be detected on chest X-ray and they were also 
more infrequent and limited on chest CT than in our previous reports. There was no 
agreement between X-ray and CT as a diagnostic tool for radiological pneumonitis. 
There was, furthermore, no relation between symptomatic and radiological RP on 
chest X-ray or CT in the current series, which can be due to the very few symptomatic 
cases. Ipsilateral V13 was most strongly an independently related with mild-severe 
radiological changes on CT. Thus, chest CT was a more sensitive method to detect 
small affected volumes than X-ray. 
Also Quality of Life was very little affected by RT in the present cohort of irradiated 
BC women. Due to pre-RT chemotherapy, the patients started with higher scores of 
fatigue. Role functioning, social functioning, and future perspective were improved 4 
months after RT compared to baseline values. Patients treated with high V13 appeared, 
however, not to recover equally well. 
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Study III 
The effect of adjuvant BC RT with modern treatment planning and the incorporation 
of an ipsilateral lung dose volume constraints of V20 ≤ 30 % on short-term pulmonary 
function was analysed in this report and compared with an earlier treatment series in 
which a constraint was not used. The mean changes in VC (-0.11 L vs. -0.15 L) and 
DLCO (-0.20 mmol/kPa min vs. -0.39 mmol/kPa min) appeared lower than in our 
previous series. We found no relation between the studied dosimetric factors nor co-
variates and PFTs changes, except for pre-RT chemotherapy and less post-RT DLCO 
reduction. This was probably influenced by the administration of chemotherapy before 
start of RT. In future trials, base line PFTs should be performed before start of any 
therapy. 
Study IV 
This study was a long-term follow-up of pulmonary side-effects in adjuvant BC RT 
without lung dose volume constraints in our previously studied cohort of patients. 
Regional CT abnormalities and PFTs changes found 4 months after RT were still 
detected after a median follow-up of 11 years. There was a statistical correlation 
between V20 and CT-scoring but no statistical correlation between V20 and VC-
changes. As the magnitude of the chronic VC-decline, -15 %, and the radiological 
abnormalities could be of clinical importance it is of value to pursuit to reduce the 
volume of incidentally irradiated lung.  
Study V 
This study evaluated the long-term cardiac effect of radiation exposure in women 
treated with RT for BC. The rates of major coronary events increased linearly with the 
mean dose to the heart by 7.4 % per Gy, without any apparent threshold. The risk 
started within 5 years after RT and continued into the third decade after treatment. The 
proportional increase in the rate per Gy was similar in woman with and without cardiac 
risk factors at the time for treatment. Thus, women with pre-existing cardiac risk 
factors had a greater absolute risk from radiotherapy than other women. 
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12. Future perspectives  
Radiotherapy after BC surgery reduces local recurrences and prolongs breast cancer 
specific survival. However, studies have also shown that women treated for more than 
three decades ago still experience late side-effects. Longer follow-up of the more 
recent large studies, which included modern RT-techniques, will likely show reduced 
doses to the heart and lung and fewer side-effects. However, we do not have enough 
knowledge on the long-term effects from the new, potentially lung- and cardio-toxic, 
systemic therapies. It is therefore of great value to continue monitoring BC patients 
undergoing combination therapy with respect to cardio-pulmonary side-effects and to 
identify genetic factors associated with radiosensitivity. Patients with BC should be 
informed about the benefits and potential risks with RT as well as the risk of smoking. 
Risk factors for heart disease, e.g. hypertension, high cholesterol levels, and diabetes, 
should be identified and treated. It is also of importance to further develop and 
implement the new RT-techniques, e.g. respiratory gating and active breathing control, 
to lower incidental dose to the heart. In some selected cases partial breast irradiation 
could be an option but this, however, requires good surgical margins and negative 
axillary lymph nodes.  The present work on national guidelines for target delineation 
and the construction of a cross sectional atlas for CTV and PTV in BC is also of 
importance. 
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